ProQR Therapeutics NV (PRQR)
1.95
+0.12
(+6.56%)
USD |
NASDAQ |
May 31, 16:00
1.95
0.00 (0.00%)
After-Hours: 20:00
ProQR Therapeutics Enterprise Value: 53.04M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 53.04M |
| May 30, 2024 | 43.24M |
| May 29, 2024 | 43.24M |
| May 28, 2024 | 44.05M |
| May 24, 2024 | 47.32M |
| May 23, 2024 | 48.14M |
| May 22, 2024 | 52.22M |
| May 21, 2024 | 48.95M |
| May 20, 2024 | 50.59M |
| May 17, 2024 | 52.22M |
| May 16, 2024 | 50.59M |
| May 15, 2024 | 49.77M |
| May 14, 2024 | 55.89M |
| May 13, 2024 | 55.49M |
| May 10, 2024 | 55.49M |
| May 09, 2024 | 57.12M |
| May 08, 2024 | 57.12M |
| May 07, 2024 | 56.30M |
| May 06, 2024 | 58.75M |
| May 03, 2024 | 57.94M |
| May 02, 2024 | 56.30M |
| May 01, 2024 | 57.12M |
| April 30, 2024 | 52.22M |
| April 29, 2024 | 54.67M |
| April 26, 2024 | 52.22M |
| Date | Value |
|---|---|
| April 25, 2024 | 53.85M |
| April 24, 2024 | 57.94M |
| April 23, 2024 | 58.75M |
| April 22, 2024 | 57.12M |
| April 19, 2024 | 56.30M |
| April 18, 2024 | 45.69M |
| April 17, 2024 | 48.95M |
| April 16, 2024 | 57.12M |
| April 15, 2024 | 60.79M |
| April 12, 2024 | 73.45M |
| April 11, 2024 | 81.62M |
| April 10, 2024 | 78.35M |
| April 09, 2024 | 88.97M |
| April 08, 2024 | 67.73M |
| April 05, 2024 | 74.27M |
| April 04, 2024 | 71.82M |
| April 03, 2024 | 67.33M |
| April 02, 2024 | 65.28M |
| April 01, 2024 | 72.63M |
| March 31, 2024 | 80.79M |
| March 28, 2024 | 59.58M |
| March 27, 2024 | 66.91M |
| March 26, 2024 | 68.54M |
| March 25, 2024 | 67.72M |
| March 22, 2024 | 66.91M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-99.27M
Minimum
Mar 25 2022
448.31M
Maximum
Dec 16 2019
139.99M
Average
152.51M
Median
Mar 07 2023
Enterprise Value Benchmarks
| uniQure NV | -214.21M |
| Merus NV | 2.787B |
| argenx SE | 18.88B |
| Pharming Group | 549.11M |
| Pharvaris NV | 634.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.318M |
| Revenue (Quarterly) | 4.834M |
| Total Expenses (Quarterly) | 13.60M |
| EPS Diluted (Quarterly) | -0.0978 |
| Profit Margin (Quarterly) | -172.1% |
| Earnings Yield | -18.38% |
| Normalized Earnings Yield | -20.79 |